This study also showed that chemo- and/or immunotherapy of MM, despite a risk of the development of refractoriness, is capable of reinforcing checkpoint expression and T cell reactivity of PB CD4 T cells, making them more attainable to therapeutic inhibitors in relapsed MM patients only. The gene discussed is CD4; the disease is Miyoshi myopathy.